- Home
- Software Solutions
- Resources
- Corporate
News feeds from around the industry (Updated Hourly) - Updated on May 21, 2013
b3c newswire
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
>6th Monolith Summer School & Symposium to be held on May 30th - June 4th, 2014, Slovenia
>Biotage and Peptide Synthesis
>Definiens Extends Functionality of Leading Image and Data Analysis Solutions for Digital Pathology
>Medical Diagnostics Company STAT-Diagnostica Secures 22. ...
>Collaboration between SwedenBIO and the EBD Group and partneringONE® to Facilitate Partnering ...
BioSpace
>There are a Zillion Biotech Conferences. Which Should You Attend?
>Actavis Nabs Warner Chilcott, PLC for $8.5 Billion
>Coffee Lowers Risk of Rare Liver Disease, Mayo Clinic Study
>Elan Corporation PLC Spends $380 Million to Repel Royalty Pharma Bid, Eyes More Deals With $1 Billion Warchest
>Vitamin D May Treat Asthma, King's College London Study
>There are a Zillion Biotech Conferences. Which Should You Attend?
>Actavis Nabs Warner Chilcott, PLC for $8.5 Billion
>Coffee Lowers Risk of Rare Liver Disease, Mayo Clinic Study
>Elan Corporation PLC Spends $380 Million to Repel Royalty Pharma Bid, Eyes More Deals With $1 Billion Warchest
>Vitamin D May Treat Asthma, King's College London Study
BioSpace - Breaking News
>"Love Hormone" Promises Safer Births After Pfizer Inc. Flop
>Health Canada: Three Companies Recall Antipsychotic Drug Quetiapine
>Former Merck & Co., Inc. Pipefitter Files Civil Rights Lawsuit Against Company
>Serbia Arrests Eight Over Embezzlement
>Veloxis Pharmaceuticals A/S Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
>"Love Hormone" Promises Safer Births After Pfizer Inc. Flop
>Health Canada: Three Companies Recall Antipsychotic Drug Quetiapine
>Former Merck & Co., Inc. Pipefitter Files Civil Rights Lawsuit Against Company
>Serbia Arrests Eight Over Embezzlement
>Veloxis Pharmaceuticals A/S Release: Final STRATO Clinical Study Data Demonstrates Potential for LCP-TacroTM to Improve Tacrolimus-Induced Tremors
Biotech News - Business Wire
>CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors
>Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
>Medidata to Present at the 14th Annual B. Riley & Co. Investor Conference
>Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine
>Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for Diversity Alliance for Science
>CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors
>Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
>Medidata to Present at the 14th Annual B. Riley & Co. Investor Conference
>Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine
>Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for Diversity Alliance for Science
Biotech News - PR Newswire
>Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
>Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
>Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
>Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
>Complix to Present at Upcoming BioEquity Europe 2013
>Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
>Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
>Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets
>Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
>Complix to Present at Upcoming BioEquity Europe 2013
Biotechnology - Moreover
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
>Analysis of Relative Performance in the Biotechnology Industry for Shares of Incyte (INCY, ONXX, ALKS, SPPI, MITI)
>Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (CPHD, IMGN, HGSI, SGEN, RIGL)
>NIH Translational Center Should ?Raise All Boats,? BIO Says
>Immunogen, inc. reports second quarter fiscal year 2012 financial results and provides quarterly update
>Biotechnology to be 21st-century industry: Life Tech CEO
Burrill Report
>Obama Administration Offers $1 Billion for Healthcare Innovation
>Pharma to Support Early-Stage Biotechs
>Scientists Report Human Stem Cell Cloning Success
>Supreme Court Rules Unanimously in Favor of Monsanto
>Saving Normal
>Obama Administration Offers $1 Billion for Healthcare Innovation
>Pharma to Support Early-Stage Biotechs
>Scientists Report Human Stem Cell Cloning Success
>Supreme Court Rules Unanimously in Favor of Monsanto
>Saving Normal
CenterWatch - Clinical Trials
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
>Sanofi's $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend
>New Quintiles initiative saves investigative sites the time, and cost, of patient recruitment advertising
>Technology companies adapt interactive video concepts for clinical trial informed consent
>CRI buys Lifetree, combining investigative sites on both coasts and across all trial phases
>New $1b NIH center will tackle early-stage drug development to ease industry risk of failure
Clinical Trials - Business Wire
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
>STENTYS Self-Apposing® Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
>Enzo Biochem Schedules Teleconference to Discuss Second Quarter Results on March 13, 2013 at 8:30 AM E.T.
>Research and Markets: Thromboembolism Global Clinical Trials Review, H1, 2013
>RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
>Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure
Clinical Trials - PR Newswire
>Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013
>New Colonoscope Provides Ground-Breaking View Of Colon
>Benvenue Medical Completes Follow-Up Phase in KAST Study Evaluating Kiva® VCF Treatment System vs. Balloon Kyphoplasty
>Vitamin D Supplements May Help Relieve Symptoms Related To Crohn's
>Coffee Consumption Associated With Reduced Risk Of Autoimmune Liver Disease
>Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013
>New Colonoscope Provides Ground-Breaking View Of Colon
>Benvenue Medical Completes Follow-Up Phase in KAST Study Evaluating Kiva® VCF Treatment System vs. Balloon Kyphoplasty
>Vitamin D Supplements May Help Relieve Symptoms Related To Crohn's
>Coffee Consumption Associated With Reduced Risk Of Autoimmune Liver Disease
CNN Top Stories
>Cartoons that scare Syria's leader
>Singer gets anthem very wrong
>See singer Miguel's stage jump fail
>Watch grizzly bear try to eat camera
>Acid attack victim: 'I had no hope'
>Cartoons that scare Syria's leader
>Singer gets anthem very wrong
>See singer Miguel's stage jump fail
>Watch grizzly bear try to eat camera
>Acid attack victim: 'I had no hope'
Contract Pharma
>Actavis to Acquire Warner Chilcott
>Sparta Systems Launches TrackWise Analytics
>Aridis Acquires Kenta mAb Portfolio
>AbbVie, Galapagos Extend Collaboration
>QPharma Appoints Medical Officer
>Actavis to Acquire Warner Chilcott
>Sparta Systems Launches TrackWise Analytics
>Aridis Acquires Kenta mAb Portfolio
>AbbVie, Galapagos Extend Collaboration
>QPharma Appoints Medical Officer
FDA Drugs- What's New
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
>FDA Drug Safety Communication: FDA approves label changes for zolpidem products, including new dosing and a recommendation to avoid driving the day after Ambien CR use
>FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children
>Drug Safety Communication: FDA warns about potential medication errors resulting from confusion regarding nonproprietary name for breast cancer drug Kadcyla (ado-trastuzumab emtansine)
>FAERS Quarterly Data Files Documentation
>FDA Drug Safety Communication: FDA limits duration and usage of Samsca (tolvaptan) due to possible liver injury leading to organ transplant or death
FDA News - Business Wire
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>Biogen Idec Submits Application to FDA for Approval of PLEGRIDY? (Peginterferon Beta-1a) in Multiple Sclerosis
>Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY? (Peginterferone Beta-1a) per la sclerosi multipla
>Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY? (peginterféron bêta-1a) contre la sclérose en plaques
>Biogen Idec reicht Zulassungsantrag für PLEGRIDY? (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein
>Samenvatting: Biogen Idec vraagt goedkeuring aan bij FDA voor PLEGRIDY (Peginterferon Beta-1a) bij multiple sclerosis
>Biogen Idec Submits Application to FDA for Approval of PLEGRIDY? (Peginterferon Beta-1a) in Multiple Sclerosis
>Biogen Idec presenta all'FDA una domanda di approvazione per il PLEGRIDY? (Peginterferone Beta-1a) per la sclerosi multipla
>Biogen Idec soumet une demande auprès de la FDA pour l'approbation du PLEGRIDY? (peginterféron bêta-1a) contre la sclérose en plaques
>Biogen Idec reicht Zulassungsantrag für PLEGRIDY? (Peginterferon Beta-1a) zur Behandlung der multiplen Sklerose bei der FDA ein
FDA Press Releases
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
>FDA approves new drug for advanced prostate cancer
>FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients
>FDA expands alert to health care providers about lack of sterility assurance of all sterile drug products from NuVision Pharmacy
>FDA seeks preliminary injunction against New York fish manufacturer
>FDA approves Simponi to treat ulcerative colitis
>FDA approves new drug for advanced prostate cancer
>FDA approves Nymalize--first nimodipine oral solution for use in certain brain hemorrhage patients
FDA Vaccines, Blood and Biologics - What's New
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
>Kcentra (Prothrombin Complex Concentrate (Human))
>Phlebotomy System 1.0.0
>Indication For Use - SOLX® System
>Urgent Medical Device Recall / Field Safety Notice - Micro SSP DNA Typing Trays
>Guidance for Industry: Blood Establishment Computer System Validation in the User's Facility
FierceBiotech
>Pfizer picks up the pieces after its armed antibody crashes in PhIII
>Karyopharm grabs $48M round for pipeline work
>FDA bestows 'Breakthrough Therapy' status to drug for fatal infant disease
>Pentagon adviser quietly pocketed biotech's cash while promoting its interests
>FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
>Pfizer picks up the pieces after its armed antibody crashes in PhIII
>Karyopharm grabs $48M round for pipeline work
>FDA bestows 'Breakthrough Therapy' status to drug for fatal infant disease
>Pentagon adviser quietly pocketed biotech's cash while promoting its interests
>FDA: Merck's sleep drug suvorexant effective, but safety issues draw heavy flak
FierceBiotech IT
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
>Drugmaker UCB taps IBM for digital medicine effort
>Life sciences VC firm launches 'crowdfunding' site for limited crowd
>Pfizer-backed analysis finds dearth of patient-reported outcomes in trials
>Chinese drug giant tackles drug counterfeiting with mobile service
>InSilico Genomics grabs $1.5M for fledgling bioinformatics biz
>Drugmaker UCB taps IBM for digital medicine effort
>Life sciences VC firm launches 'crowdfunding' site for limited crowd
FierceBiotech Research
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
>Drug boosts effectiveness of radiation therapy for brain tumors
>Scientists use cloning method to create embryonic stem cells
>Stem cell therapy treats common pregnancy complication
>Researchers pinpoint protein involved in cancer cell death
>Alnylam reports positive preclinical results for RNAi therapy to treat rare metabolic disease
>Drug boosts effectiveness of radiation therapy for brain tumors
>Scientists use cloning method to create embryonic stem cells
>Stem cell therapy treats common pregnancy complication
FiercePharma
>Shire eyes takeover protection as bid rumors swirl, Mail says
>Ex-HGS director draws fire for plugging anthrax drug at Pentagon
>Women want Apotex to pay for unwanted pregnancies
>GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
>JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
>Shire eyes takeover protection as bid rumors swirl, Mail says
>Ex-HGS director draws fire for plugging anthrax drug at Pentagon
>Women want Apotex to pay for unwanted pregnancies
>GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
>JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets
FiercePharma Manufacturing
>Impax brings in big guns to get on top of manufacturing problems
>Apotex sued over problems on contraceptive packaging line
>China arrests dozens, seizes tens of millions of counterfeit drugs
>Worker hurt in 'flash fire' at Amgen facility
>CEO of J&J OTC unit in Korea faces criminal action over plant foul-up
>Impax brings in big guns to get on top of manufacturing problems
>Apotex sued over problems on contraceptive packaging line
>China arrests dozens, seizes tens of millions of counterfeit drugs
>Worker hurt in 'flash fire' at Amgen facility
>CEO of J&J OTC unit in Korea faces criminal action over plant foul-up
FierceVaccines
>Taliban drops campaign against polio vaccine
>Human-to-human coronavirus spread looks likely
>Novartis taps synthetic biology to speed vax development
>Indian rotavirus vax set to undercut GSK and Merck
>Media reports used to track global vaccine backlash
>Taliban drops campaign against polio vaccine
>Human-to-human coronavirus spread looks likely
>Novartis taps synthetic biology to speed vax development
>Indian rotavirus vax set to undercut GSK and Merck
>Media reports used to track global vaccine backlash
Health News - BizJournals.com
>Fiscal bureau says health care changes could be costly to taxpayers
>Pentagon: UnitedHealth still too slow
>Winston-Salem called a 'shining example' of economic development
>Could Winston-Salem become the home of a major vaccine center?
>InnovateLTC will co-sponsor Chicago entrepreneur competition
>Fiscal bureau says health care changes could be costly to taxpayers
>Pentagon: UnitedHealth still too slow
>Winston-Salem called a 'shining example' of economic development
>Could Winston-Salem become the home of a major vaccine center?
>InnovateLTC will co-sponsor Chicago entrepreneur competition
Health News - CNBC
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
>Germany's Merck Serono to produce medicines in UAE
>Germany's Merck Serono to produce medicines in UAE
>Analysis: Drugmakers step up search for hearing loss medicines
>Grand jury probing meningitis-linked pharmacy: newspaper
>Small Employers Weigh Impact of Providing Health Insurance
Health News - Fox Business
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
>Employers Grateful for Proposed Tax Breaks, But Still Scared
>Employers Grateful for Proposed Tax Breaks, Still Scared
>Insmed Shares Drop as FDA Halts Study After Rat Test Results
>Week Ahead: A Flood Of 2Q Earnings
>Pfizer Drug Raises Heart Attack Risk: Study
Inside Industry - Gen
>Collaboration Aims to Create In Vitro Human Skin
>Actavis Acquiring Warner Chilcott for $8.5B
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
>Collaboration Aims to Create In Vitro Human Skin
>Actavis Acquiring Warner Chilcott for $8.5B
>Amgen Forms Joint Venture to Sell Vectibix in China
>FDA OKs Novartis' Childhood Arthritis Drug
>ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
Marketwire - Pharma and Biotech
>Atossa Genetics to Sponsor Screenings of Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013
>Plandai Biotechnology, Inc. Product Proven to Decrease Healing Time of Sports-Related Injuries
>Quantum Health Ranked 26th on List of Top 50 Fastest-Growing Women-Owned/Led Companies in North America
>Nihon Kohden America Puts Spotlight on Enterprise Monitoring Solutions at NTI
>YFRM Technologies, Inc. Completes Acquisition of the Integrative Stem Cell Institute
>Atossa Genetics to Sponsor Screenings of Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013
>Plandai Biotechnology, Inc. Product Proven to Decrease Healing Time of Sports-Related Injuries
>Quantum Health Ranked 26th on List of Top 50 Fastest-Growing Women-Owned/Led Companies in North America
>Nihon Kohden America Puts Spotlight on Enterprise Monitoring Solutions at NTI
>YFRM Technologies, Inc. Completes Acquisition of the Integrative Stem Cell Institute
MassBio News
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
>Policy Update
>Return of BioPharm America? 2013 to Boston will draw leading international life science dealmakers to northeast
>Adrian Haber and Rahi Punjabi Selected as Massachusetts BioGENEius Delegates
>Not in it Alone: Diabetes Network Founder Finds His Voice
>MASY SYSTEMS OPENS NEW FACILITY OFFERING 6,200 CU. FT. OF -75°C STORAGE SPACE
Medical Pharma - PR Newswire
>International Medical Group and Sister Cities International Bring Insurance Solutions to International Travelers
>Lehigh Valley Expands Fleet of Superbug-Slaying Robots
>'How Safe Are Prescription Drug Doses if Patients in Clinical Trials Did Not Take the Full Dose?' Asks Consumer Health Information Corporation
>New Research Proves Clinical Pathways Can Reduce Cancer Care Costs and Improve Quality While Increasing Physician Reimbursement
>Lesley Visser to Speak at Astellas Presents Executive Women's Day at the Crowne Plaza Invitational at Colonial
>International Medical Group and Sister Cities International Bring Insurance Solutions to International Travelers
>Lehigh Valley Expands Fleet of Superbug-Slaying Robots
>'How Safe Are Prescription Drug Doses if Patients in Clinical Trials Did Not Take the Full Dose?' Asks Consumer Health Information Corporation
>New Research Proves Clinical Pathways Can Reduce Cancer Care Costs and Improve Quality While Increasing Physician Reimbursement
>Lesley Visser to Speak at Astellas Presents Executive Women's Day at the Crowne Plaza Invitational at Colonial
National Center for Biotechnology Information
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
>NCBI Announcements
>NCBI News
>NLM Catalog New and Noteworthy
>PubMed Central News
>GEO Series Releases
Nature Biotechnology
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
>Do no harm
>Raising standards
>Drugmakers plow more resources into autism
>Billions spent on rare diseases
>Footrace to clinic heats up for T-cell nuclear receptor inhibitors
New York Times- Biotechnology
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
>Building a $325,000 Burger
>A Dream of Trees Aglow at Night
>Double Helix Serves Double Duty
>Don’t Be Afraid of Genetic Modification
>Improper Efforts to Limit Competitive Drugs
New York Times- Pharmaceuticals
>Pills Tracked From Doctor to Patient to Aid Drug Marketing
>Melanoma Treatment Harnesses Immune System to Combat Cancer Cells
>Estimated Health Costs in Retirement Drop
>Generic Drug Maker Pleads Guilty in Federal Case
>Doctors' Lucrative Industry Ties
>Pills Tracked From Doctor to Patient to Aid Drug Marketing
>Melanoma Treatment Harnesses Immune System to Combat Cancer Cells
>Estimated Health Costs in Retirement Drop
>Generic Drug Maker Pleads Guilty in Federal Case
>Doctors' Lucrative Industry Ties
OnBioVC
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
>OptiMedica, Corp.: Series E $35M
>iRythm Technologies, Inc.: Series C $1.5M
>Edison Pharmaceuticals, Inc.: Series F $20M
>New Haven Pharmaceuticals, Inc.: Series A $6.6M
>Kiadis Pharma, B.V.: Series D $12.8M
Outsourcing-Pharma
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
>TFS Sees Increase in Modularization, Shorter Construction Timelines
>AlpVision's iPhone Tech Offers Authentication in War on Counterfeits
>AMRI Exec Discusses 'New Bar' in FDA Enforcement
>Happy holidays from William Reed Business Media!
>Aesica says academic partnerships are key for CMOs
Pharma News - Business Wire
>CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors
>Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
>Medidata to Present at the 14th Annual B. Riley & Co. Investor Conference
>Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine
>Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for Diversity Alliance for Science
>CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors
>Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
>Medidata to Present at the 14th Annual B. Riley & Co. Investor Conference
>Liquidia Technologies Announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal Vaccine
>Caligor Rx Managing Director Tammy Bishop Elected to Board of Directors for Diversity Alliance for Science
Pharma News - PharmiWeb
>ClinTec International expands further in MENA region with proposed opening of Istanbul Office
>Padma Bhushan Dr. Nandkishore Shamrao Laud to receive Lifetime Achievement Award at India Leadership Conclave 2013
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>CML Drug Revenue in Japan to Grow, Despite Global Decline
>Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices
>ClinTec International expands further in MENA region with proposed opening of Istanbul Office
>Padma Bhushan Dr. Nandkishore Shamrao Laud to receive Lifetime Achievement Award at India Leadership Conclave 2013
>Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report
>CML Drug Revenue in Japan to Grow, Despite Global Decline
>Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices
Pharma News - PR Newswire
>New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
>Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
>Diclegis® Now Available Nationwide To Treat Pregnant Women With Nausea And Vomiting Of Pregnancy (NVP)
>BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
>U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015
>New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
>Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
>Diclegis® Now Available Nationwide To Treat Pregnant Women With Nausea And Vomiting Of Pregnancy (NVP)
>BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference
>U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015
Pharmaceutical - Moreover
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
>: Pharmaceuticals look to cure pipeline concerns
>Drug firms sign up to new tropical disease fight
>Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are No
>Micro Labs attracts private equity and pharma interest: VCCircle
>Novartis net dips by 5.3% to Rs.38 crore in Q3
PR Leap - Biotech
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
>West Chester, PA, Author Publishes "All in Good Time"
>Newly Published Book Details the Attempted Recall of Michigan Governor Granholm
>Burlington, New Jersey, Author Publishes New Novel
>Abcam Signs Licence With The University Of Bari To Offer Lp-44 – A Novel, Selective 5-Ht7 Agonist
>Otogenetics' Now Offers "Triple Guarantee" on NGS Services
PRWeb - Biotechnology
>Possible Mold Re-infestation Gets Guilmette School Scheduled for...
>Vital Imaging Makes Greater Commitment into MRI Research
>Inflamax Research selected by the Immune Tolerance Network and the...
>Nanonex Announces the Shipment and Installation of an Innovative...
>Revolutionary Science Announces New Automatic and Manual Colony...
>Possible Mold Re-infestation Gets Guilmette School Scheduled for...
>Vital Imaging Makes Greater Commitment into MRI Research
>Inflamax Research selected by the Immune Tolerance Network and the...
>Nanonex Announces the Shipment and Installation of an Innovative...
>Revolutionary Science Announces New Automatic and Manual Colony...
PRWeb - Pharmaceuticals
>Global Vision's Text Comparison Software Docu-Proof Recognized by...
>CEO of Execution Management and Strategic Planning Software Company...
>MD Aligne is the Best Choice for Supplemental Healthcare Due to...
>Brooklyn Smiles, the Premier Dentist in Brooklyn, Becomes a Top 100...
>Leading South Florida Pain Clinic, Prime Care, Now Offering Board...
>Global Vision's Text Comparison Software Docu-Proof Recognized by...
>CEO of Execution Management and Strategic Planning Software Company...
>MD Aligne is the Best Choice for Supplemental Healthcare Due to...
>Brooklyn Smiles, the Premier Dentist in Brooklyn, Becomes a Top 100...
>Leading South Florida Pain Clinic, Prime Care, Now Offering Board...
Scientific American
>Search for Survivors Races On as 91 Feared Dead in Tornado-Hit Oklahoma
>Why Penguins Cannot Fly
>Drought Gobbles Up Texas Turkey Hunt
>Heat Deaths in New York City Predicted to Rise
>Stress Makes Gorilla Glass Stronger
>Search for Survivors Races On as 91 Feared Dead in Tornado-Hit Oklahoma
>Why Penguins Cannot Fly
>Drought Gobbles Up Texas Turkey Hunt
>Heat Deaths in New York City Predicted to Rise
>Stress Makes Gorilla Glass Stronger
Sports - ESPN Basketball
>Freshman Impact: Ohio State
>Ex-Rutgers coach Rice receiving counseling
>Florida Intl. guard Smith transfers to Minnesota
>Black transfers to Kansas, can play right away
>Report: Coach K considering Team USA return
>Freshman Impact: Ohio State
>Ex-Rutgers coach Rice receiving counseling
>Florida Intl. guard Smith transfers to Minnesota
>Black transfers to Kansas, can play right away
>Report: Coach K considering Team USA return
Sports News - ESPN
>100 numbers to know for the 2013 college football season
>QB Lunt mulls Illinois after visit, sources say
>Former Arkansas QB Mitchell picks NC State
>McCartney back on WVU roster after 6 months
>Sources: C-USA to put team in Military Bowl
>100 numbers to know for the 2013 college football season
>QB Lunt mulls Illinois after visit, sources say
>Former Arkansas QB Mitchell picks NC State
>McCartney back on WVU roster after 6 months
>Sources: C-USA to put team in Military Bowl
Xconomy Life Sciences
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
>Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
>NanoString Technologies Maneuvers In Line for $86M IPO
>Accelerate LI's Lofty Goal: Create the Next U.S. Innovation Cluster
>Zillions of Biotech Conferences Want You. Which Should You Attend?
>XBiotech Takes Aim at Inflammation That Weakens Cancer Patients
Yahoo Biotech News
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)
>Slow, costly process stymies generic biotech drugs (Reuters)
>Analysis: Slow, costly process stymies generic biotech drugs (Reuters)
>Waves Break Coral Embryo into Identical Twins (LiveScience.com)
>Autoinjector Version of MS Drug Approved (HealthDay)
>Fake Avastin had salt, starch, chemicals: Roche (Reuters)